COlchicine for Left VEntricular Remodeling Treatment in Acute Myocardial Infarction

PHASE2CompletedINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

July 23, 2018

Primary Completion Date

November 8, 2020

Study Completion Date

August 16, 2021

Conditions
Myocardial Infarction
Interventions
DRUG

Colchicine group (experimental arm)

In the experimental group, patients will receive colchicine, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily (b.i.d) for 5 days.

DRUG

Placebo group (control arm)

In the placebo group, patients will receive placebo, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily for 5 days.

Trial Locations (8)

69677

Hôpital Louis Pradel, Bron

Unknown

Centre Hospitalier Universitaire Angers, Angers

Hôpital Saint Joseph, Lyon

CHU Arnaud de Villeneuve, Montpellier

CHU de Mulhouse, Mulhouse

CHU de Poitiers, Poitiers

CHU de Rangueil, Toulouse

CHRU de Tours, Tours

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03156816 - COlchicine for Left VEntricular Remodeling Treatment in Acute Myocardial Infarction | Biotech Hunter | Biotech Hunter